Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry.
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
MIRICO Ltd. is a UK-based laser spectroscopy instrumentation company formed in 2015 as a spin-out from the Science and Technology Facilities Council. The technology underpinning MIRICO was developed by the RAL Space Laser Spectroscopy Team, led by Dr. Damien Weidmann. The laser spectroscopy team consists of 8 senior scientists who carry out cutting edge research and development. Over the years they have developed a range of spectroscopy techniques that overcome the major downfalls of current technologies. The company was formed to commercialise and take these technologies to market.
Lineat is a manufacturer specializing in fiber tape products, particularly focusing on carbon fiber tapes produced through aligned formable fiber technology. This innovative approach allows for the creation of aligned discontinuous fiber tapes that demonstrate mechanical performance comparable to traditional continuous fiber composites. By simplifying the composite manufacturing process, Lineat enhances formability and streamlines both manual and automated operations. Additionally, the company has implemented a closed-loop water circulation system aimed at improving lifecycle assessment (LCA), reflecting its commitment to sustainability in production practices.
MitoRx Therapeutics is a biotechnology company focused on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company targets a range of conditions, including neuromuscular disorders, metabolic diseases, and dementia. By specializing in mitochondrial-protective therapies, MitoRx seeks to address the progression of challenging diseases, particularly rare indications, while also engaging in partnerships for broader applications. Their work enables healthcare professionals to potentially halt the decline associated with dystrophy and neurodegeneration.
Q5D manufactures tools to automate the production of wiring harness for all industrial sectors.
Atheras Analytics specializes in developing artificial intelligence-driven software tools delivered as a service for the design and operation of Ka-band and Q/V-band satellite networks. The company's innovative solutions focus on mitigating weather-related disruptions and enhancing network and service availability. By utilizing machine-learning algorithms derived from a comprehensive database of satellite signal propagation time-series measurements, Atheras Analytics enables satellite operators to optimize the design of their multi-gateway networks. This optimization not only improves performance but also ensures cost-effective solutions for operators in the satellite communications sector.
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Vector Photonics is a spin-out company from the University of Glasgow and is based in Glasgow, Scotland, one of the UK and world’s Optical and Photonics centres of excellence.
Cytoseek Limited, founded in 2017 and based in Bristol, United Kingdom, specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. As a spinout from the University of Bristol, the company utilizes a unique cell membrane augmentation technology that enhances cell therapies by adding new functionalities, such as tissue-specific targeting and improved cell survivability. Currently, Cytoseek is conducting proof of principle studies to validate the effectiveness of its therapies and is actively seeking partnerships with other cell therapy companies to advance these treatments into clinical settings, ultimately aiming to improve human health.
Antiverse operates a pioneering computational platform designed for antibody drug discovery, focusing on the rapid prediction of antibody-antigen binding. By leveraging advanced machine learning techniques alongside cell-free protein synthesis, Antiverse can identify high-affinity antibodies for specific antigen targets. The platform allows customers to submit antigen target sequences, which are then subjected to high-throughput screening to determine the optimal antibody sequence. This innovative approach enables the delivery of antibody candidates within a single day, significantly streamlining the discovery process and reducing the traditional timeline by 3 to 18 months. Antiverse’s technology aims to assist pharmaceutical companies and contract research organizations in overcoming challenges associated with difficult targets in antibody therapeutics development.
Linear Diagnostics Limited is a diagnostics company based in Birmingham, United Kingdom, that specializes in developing a novel diagnostic platform technology leveraging linear dichroism (LD). Founded in 2011, the company focuses on a wide range of applications, including the detection of antibiotic resistance in infections and the identification of bacteria responsible for crop spoilage. The platform enables simultaneous measurement of multiple targets from a single sample and utilizes various molecular recognition methods to enhance detection capabilities. Additionally, Linear Diagnostics offers a handheld reader for measuring linear dichroism signals, providing a streamlined and efficient approach to molecular diagnostics. The technology represents a significant advancement over existing methods, facilitating quicker and more accurate testing processes.
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy, safety, and economy.
Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.
Tropic Biosciences UK LTD is a biotechnology company focused on developing high-performing commercial varieties of tropical crops, specifically targeting the coffee and banana industries. Established in 2016 and headquartered in Norwich, United Kingdom, the company employs advanced non-GMO gene editing technologies to enhance crop performance while promoting grower wellbeing and consumer health. Through its innovative approach, Tropic Biosciences aims to improve sustainable agricultural practices and address the challenges faced by tropical crop producers.
MicrofluidX Ltd is a company focused on advancing cell bioprocessing for autologous cell and gene therapy manufacturing. Founded in 2018 and headquartered in London, United Kingdom, the company has developed an innovative microfluidic bioprocessing system that integrates various cell culture functions, including seeding, expansion, differentiation, transduction, washing, sorting, concentration, sampling, and harvesting within a single, automated, closed system. This technology addresses challenges related to process control, scalability, and cost in cell bioprocessing, enabling biologists to efficiently conduct process development by exploring numerous cell culture conditions.
Ikarovec
Seed Round in 2020
Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Pencil Biosciences aims to develop a novel, programmable genome-modulation tool that overcomes the challenges associated with the technologies currently available.
Cytoseek Limited, founded in 2017 and based in Bristol, United Kingdom, specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. As a spinout from the University of Bristol, the company utilizes a unique cell membrane augmentation technology that enhances cell therapies by adding new functionalities, such as tissue-specific targeting and improved cell survivability. Currently, Cytoseek is conducting proof of principle studies to validate the effectiveness of its therapies and is actively seeking partnerships with other cell therapy companies to advance these treatments into clinical settings, ultimately aiming to improve human health.
C-Major Medical is dedicated to addressing the persistent issue of needle stick injuries (NSIs) in medical environments. Despite significant efforts and legislation aimed at reducing these incidents, the frequency of NSIs has not declined sufficiently. To tackle this challenge, C-Major Medical develops innovative safety devices, including a syringe and blood collection system designed specifically to minimize the risk of NSIs and prevent contaminating aerosols. By promoting the safety of healthcare staff, the company's solutions aim to enhance practices in hospitals, clinics, and other medical settings, ultimately contributing to a safer working environment for medical practitioners.
Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.
Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.
Eagle Genomics Ltd. specializes in providing data management and analysis solutions for the healthcare, pharmaceutical, biotech, and personal care sectors. Founded in 2008 and based in Cambridge, United Kingdom, with additional offices in the United States, Germany, and India, the company focuses on the management and analysis of genomic data, particularly through next-generation sequencing technologies. Its services encompass NGS data management, analysis, visualization, biomarker discovery, and custom software development. The company also offers pipeline design services and a web-based platform, ElasticAP, for managing life sciences research and development data in the cloud. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics helps clients in drug development, personal hygiene, and agri-tech industries maximize the value of their research and development data, addressing challenges associated with the increasing volume of life sciences data.
Antiverse operates a pioneering computational platform designed for antibody drug discovery, focusing on the rapid prediction of antibody-antigen binding. By leveraging advanced machine learning techniques alongside cell-free protein synthesis, Antiverse can identify high-affinity antibodies for specific antigen targets. The platform allows customers to submit antigen target sequences, which are then subjected to high-throughput screening to determine the optimal antibody sequence. This innovative approach enables the delivery of antibody candidates within a single day, significantly streamlining the discovery process and reducing the traditional timeline by 3 to 18 months. Antiverse’s technology aims to assist pharmaceutical companies and contract research organizations in overcoming challenges associated with difficult targets in antibody therapeutics development.
Tropic Biosciences UK LTD is a biotechnology company focused on developing high-performing commercial varieties of tropical crops, specifically targeting the coffee and banana industries. Established in 2016 and headquartered in Norwich, United Kingdom, the company employs advanced non-GMO gene editing technologies to enhance crop performance while promoting grower wellbeing and consumer health. Through its innovative approach, Tropic Biosciences aims to improve sustainable agricultural practices and address the challenges faced by tropical crop producers.
Cytoseek Limited, founded in 2017 and based in Bristol, United Kingdom, specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. As a spinout from the University of Bristol, the company utilizes a unique cell membrane augmentation technology that enhances cell therapies by adding new functionalities, such as tissue-specific targeting and improved cell survivability. Currently, Cytoseek is conducting proof of principle studies to validate the effectiveness of its therapies and is actively seeking partnerships with other cell therapy companies to advance these treatments into clinical settings, ultimately aiming to improve human health.
Glialign specializes in regenerative technologies aimed at enhancing peripheral nerve repair. The company is developing a novel cell therapy that serves as a living nerve growth guide, designed to replace traditional nerve grafts, which often require harvesting nerves from other body parts. Current treatments for peripheral nerve injuries are only effective in less than half of the cases, highlighting the need for more reliable solutions. Glialign's approach provides an off-the-shelf alternative, enabling healthcare providers to facilitate nerve regeneration and improve functional recovery for patients suffering from nerve injuries.
MIRICO Ltd. is a UK-based laser spectroscopy instrumentation company formed in 2015 as a spin-out from the Science and Technology Facilities Council. The technology underpinning MIRICO was developed by the RAL Space Laser Spectroscopy Team, led by Dr. Damien Weidmann. The laser spectroscopy team consists of 8 senior scientists who carry out cutting edge research and development. Over the years they have developed a range of spectroscopy techniques that overcome the major downfalls of current technologies. The company was formed to commercialise and take these technologies to market.
Atelerix Limited provides storage and transportation of cells and tissues at room temperature. The company provides suspended cells, planted cells, and tissues. It also discovers and tests new drugs, develops cell therapies, and stores stem cells. The company was founded in 2006 and is based in Cambridge, United Kingdom.
Eagle Genomics Ltd. specializes in providing data management and analysis solutions for the healthcare, pharmaceutical, biotech, and personal care sectors. Founded in 2008 and based in Cambridge, United Kingdom, with additional offices in the United States, Germany, and India, the company focuses on the management and analysis of genomic data, particularly through next-generation sequencing technologies. Its services encompass NGS data management, analysis, visualization, biomarker discovery, and custom software development. The company also offers pipeline design services and a web-based platform, ElasticAP, for managing life sciences research and development data in the cloud. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics helps clients in drug development, personal hygiene, and agri-tech industries maximize the value of their research and development data, addressing challenges associated with the increasing volume of life sciences data.
Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.
Camstech Ltd is an early-stage company focused on developing innovative biochemical sensing technologies aimed at enhancing point-of-care diagnostics. Established in 2014 and having graduated from the CERN Business Incubation Centre at Harwell Campus, the company is now located at the STFC’s Campus Technology Hub in Daresbury Laboratory. Camstech seeks to commercialize a unique sensing technology initially developed by Professor Pankaj Vadgama, targeting applications in life sciences, biotechnology, and medical diagnostics. The company is creating advanced electrodes equipped with electrochemical sensors, which offer significant advantages over traditional screen-printed electrodes, including improved stability and resistance to biofouling. This technology positions biotechnology firms to create tests for emerging biomarkers, facilitating more effective monitoring and diagnostics.
Cagen is a synthetic biology company.
MyoDOPA
Seed Round in 2018
MyoDOPA is develops a novel therapeutic profile providing efficient treatment.
SFH Oxford Ltd. is a UK-based company that specializes in developing and marketing innovative healthcare technologies aimed at improving the treatment of venous leg ulcers, a common chronic wound. Founded in 2011 and located in Didcot, the company offers a range of products, including Graducheck, a sensor-based technology that enhances the application of compression bandages, and AFT graduated compression socks, which ensure appropriate compression levels. Additionally, SFH Oxford produces K-gel, a wound dressing designed to aid in healing. The company is actively involved in clinical and field trials for several of its products, which are demonstrating promising results. SFH Oxford's leadership team possesses extensive experience in medical device technology and wound care, focusing on delivering optimized care solutions for both patients and healthcare professionals involved in venous leg ulcer management.
C-Major Medical is dedicated to addressing the persistent issue of needle stick injuries (NSIs) in medical environments. Despite significant efforts and legislation aimed at reducing these incidents, the frequency of NSIs has not declined sufficiently. To tackle this challenge, C-Major Medical develops innovative safety devices, including a syringe and blood collection system designed specifically to minimize the risk of NSIs and prevent contaminating aerosols. By promoting the safety of healthcare staff, the company's solutions aim to enhance practices in hospitals, clinics, and other medical settings, ultimately contributing to a safer working environment for medical practitioners.
Pireta Ltd is a company focused on developing and commercializing technology for smart textiles. Established in 2017 and based in Teddington, United Kingdom, Pireta has created a unique additive process that integrates conductivity and sensors into fabrics without altering their feel or performance. This innovative approach enables the production of textiles that can serve various functions, including communication, physiological monitoring, and tracking. Pireta's technology is applicable across multiple industries, such as military, emergency services, defense, fashion, athletics, healthcare, biosciences, and RFID tagging, facilitating the creation of wearable smart garments and electronic textiles.
Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.
Puraffinity was incorporated in 2015 and is headquartered in London. The company specialises in the design of advanced materials, and has developed a bio-based novel adsorbent capable of removing highly challenging pollutants from contaminated water and wastewater. The technology utilises advanced supramolecular chemistry methods to functionalise bio-based materials designed to bind target chemicals. The company is at the forefront of developing solutions for overcoming imminent water quality challenges, whilst sustainable and positive environmental impact lies at the heart of the company’s ethos.
Cytox Limited is focused on developing products and services aimed at addressing neurodegenerative disorders, particularly Alzheimer's disease (AD). The company specializes in cellular and genetic assays that facilitate the diagnosis and treatment of AD, leveraging the cell division cycle theory of its pathogenesis. It has created a genetic-based blood test designed for early-stage risk assessment and diagnosis of Alzheimer's disease. Cytox also offers biomarker and drug-screening services to pharmaceutical companies engaged in clinical trials for AD and mild cognitive impairment treatments. By collaborating with Affymetrix, a part of Thermo Fisher Scientific, Cytox supports the development of novel therapeutics aimed at combating this growing condition, which currently affects millions worldwide. Founded in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox serves a global clientele that includes pharmaceutical and biotechnology firms, as well as research laboratories.
Tropic Biosciences UK LTD is a biotechnology company focused on developing high-performing commercial varieties of tropical crops, specifically targeting the coffee and banana industries. Established in 2016 and headquartered in Norwich, United Kingdom, the company employs advanced non-GMO gene editing technologies to enhance crop performance while promoting grower wellbeing and consumer health. Through its innovative approach, Tropic Biosciences aims to improve sustainable agricultural practices and address the challenges faced by tropical crop producers.
Linear Diagnostics Limited is a diagnostics company based in Birmingham, United Kingdom, that specializes in developing a novel diagnostic platform technology leveraging linear dichroism (LD). Founded in 2011, the company focuses on a wide range of applications, including the detection of antibiotic resistance in infections and the identification of bacteria responsible for crop spoilage. The platform enables simultaneous measurement of multiple targets from a single sample and utilizes various molecular recognition methods to enhance detection capabilities. Additionally, Linear Diagnostics offers a handheld reader for measuring linear dichroism signals, providing a streamlined and efficient approach to molecular diagnostics. The technology represents a significant advancement over existing methods, facilitating quicker and more accurate testing processes.
Nemesis Bioscience Ltd. is a biopharmaceutical company based in Cambridge, United Kingdom, focused on developing therapeutic agents that restore antibiotic sensitivity in resistant microbial pathogens. Founded in 2014, the company specializes in its innovative Nemesis Symbiotics, which are designed to directly kill pathogenic microorganisms or enhance their susceptibility to existing antibiotics. This technology addresses all classes of antibiotics and various resistance mechanisms, aiming to prevent the spread of resistance genes and maintain the effectiveness of both current and future antibiotics. In addition to treating infections, Nemesis Bioscience's solutions also have potential applications in reducing chemotherapy toxicity and inactivating virulence factors. The company has received recognition for its entrepreneurial efforts, including an award from King’s College, Cambridge, and has filed multiple international patent applications to protect its inventions.
The Electrospinning Company is a leading edge provider of electrospun nanofibre innovations, developing solutions to industrial challenges. They also work closely with academic research groups to develop novel nano-scale fibres and coatings for scientific research.
AgPlus Diagnostics Ltd. is a company specializing in the development of a diagnostic platform technology aimed at providing quantitative point-of-care products for various clinical applications, including human and veterinary diagnostics. Established in 2009 and headquartered in Sharnbrook, United Kingdom, the company designs, manufactures, and supplies diagnostic tests and accompanying readers. AgPlus Diagnostics employs an electrochemical reader and measurement system that enables personalized healthcare by delivering rapid diagnostic results based on individual biomarker profiles. This technology allows healthcare providers to make critical treatment decisions in a matter of minutes, enhancing the efficiency of patient care.
Keit Ltd. is a company based in Didcot, United Kingdom, specializing in the design and manufacture of advanced spectrometers and related instruments, particularly in the field of Fourier Transform Infrared (FTIR) spectroscopy. Founded in 2012, Keit has developed the microFTS®, a compact and robust FTIR spectrometer that excels in extreme environments, making it particularly suitable for applications in the Pharmaceutical, Chemical, Oil & Gas, and Food & Beverage industries. The microFTS® enables real-time analysis of liquid states, facilitating process monitoring and control in various manufacturing settings. Its innovative design allows for direct mounting on manufacturing vessels or connection to process lines, empowering chemical engineering and production teams to make timely and informed decisions that enhance process efficiency and optimization.
MIRICO Ltd. is a UK-based laser spectroscopy instrumentation company formed in 2015 as a spin-out from the Science and Technology Facilities Council. The technology underpinning MIRICO was developed by the RAL Space Laser Spectroscopy Team, led by Dr. Damien Weidmann. The laser spectroscopy team consists of 8 senior scientists who carry out cutting edge research and development. Over the years they have developed a range of spectroscopy techniques that overcome the major downfalls of current technologies. The company was formed to commercialise and take these technologies to market.
Jupiter Diagnostics specializes in providing rapid and cost-effective blood testing solutions through its innovative technology. Utilizing patented nano crystal labeled technology, the company enables the performance of multiple blood tests within 10 minutes, using just a small blood sample. This approach offers a significant reduction in costs, making tests approximately one-third cheaper than traditional laboratory methods. By bringing high-quality diagnostics closer to clinicians and patients, Jupiter Diagnostics facilitates a streamlined process that simplifies blood sample collection, ultimately empowering healthcare practitioners to make quicker and more informed decisions regarding patient care.
Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.
Oxford Space Systems Limited is a space technology company based in Harwell, United Kingdom, founded in 2013. The firm specializes in developing, manufacturing, and marketing deployable hardware structures for space applications, including deployable antennas, composite linear boom systems, and hinge systems. By employing innovative design techniques, such as origami, and utilizing novel proprietary materials, Oxford Space Systems creates products that are lighter, less complex, and more cost-effective than traditional alternatives. The company has achieved significant milestones, including a record for the fastest development of a new product, the AstroTube Boom, which was successfully deployed in orbit within 30 months. With a team of 18 professionals possessing over 100 years of combined experience in the space sector, Oxford Space Systems has engaged in various collaborations, including government-supported projects with leading European satellite manufacturers and commercial contracts in Asia and the U.S. In 2018, the company relocated to a custom facility within the Harwell Space Cluster, enhancing its capabilities to meet security standards for defense and security contracts.
Perfectus Biomed is a microbiological services provider that specializes in customized and accredited microbiology testing. The company focuses on tailoring antimicrobial assays and developing bespoke methods for biofilm testing, recognizing that standard testing may not be suitable for all products. By adopting a research-based approach, Perfectus Biomed collaborates closely with clients to meet their specific testing needs while ensuring rapid turnaround times. Their customer-centric service includes regular feedback, consultancy, method development, and comprehensive report writing. Additionally, they produce conference abstracts and posters based on their research findings, reinforcing their commitment to delivering high-quality, personalized microbiological testing solutions.
Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.
CHAIN Biotechnology Ltd. is a biotechnology company that specializes in developing and utilizing Clostridium bacteria for various applications, leveraging recent advancements in synthetic biology and automation to enhance fermentation processes. The company focuses on producing chiral chemicals, which are essential for a variety of products such as nutraceuticals, personal healthcare items, pharmaceuticals, and fragrances. Among its key developments are 3-hydroxybutyrate, a versatile chiral molecule, and (R)-methyl-3HB, a precursor chemical for the glaucoma treatment dorzolamide. Additionally, CHAIN Biotechnology is exploring cost-effective fermentation methods using sugar as a substrate. The company's expertise encompasses microbiology, molecular biology tools, and microbial strain development. Founded in 2014 and headquartered in London, United Kingdom, CHAIN Biotechnology is also engaged in developing therapeutic compounds aimed at addressing chronic gut-related diseases through its innovative drug development platform.
NorthRow is a web-based platform designed to enhance risk management, compliance, and anti-fraud decisions for regulated businesses. It offers a suite of features that can be utilized independently or collectively, enabling users to conduct thorough checks on individuals, companies, and identity documents. The platform streamlines onboarding processes and enhances client due diligence by continuously monitoring customer profiles for changes, which helps businesses proactively manage regulatory risks. By accessing multiple data sources, NorthRow facilitates the verification of identities and authenticates critical documents such as passports and visas, ultimately improving customer experiences while ensuring compliance with regulatory requirements.
Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.
Spectral Edge Ltd is a technology company based in Cambridge, United Kingdom, specializing in image enhancement and video personalization technologies. Founded in 2011, the company has developed patented image fusion technology that utilizes deep learning to improve image quality and visibility, particularly for color-blind individuals. Its flagship products include Phusion, which enhances images and videos by leveraging information beyond the normal visible spectrum, Eyeteq, designed to make television content more accessible to those with color vision deficiencies, and Nighteq, which reduces blue light to enhance sleep quality while maintaining visual contrast. These innovations find applications in various sectors, including computational photography, security, and consumer electronics, serving manufacturers and service providers in enhancing the viewing experience. As of December 2019, Spectral Edge operates as a subsidiary of Apple Inc.
Tokamak Energy Ltd is a private company based in Abingdon, United Kingdom, focused on the development of fusion power technology. Established in 2009, it specializes in creating compact fusion reactors known as spherical tokamaks, which offer a more efficient means of achieving high plasma pressure compared to traditional designs. The company's key products, the ST25 and ST40, utilize high-temperature superconductors and advanced materials to enhance plasma confinement and overall reactor performance. By leveraging decades of scientific research, Tokamak Energy aims to accelerate the commercial viability of fusion energy, positioning itself as a leader in the pursuit of affordable and sustainable energy solutions that contribute to global energy security while minimizing environmental impact.
Claresys Ltd. specializes in the development and supply of lens solutions tailored for covert surveillance applications. The company offers a range of products, including covert pinhole pan/tilt/zoom lenses designed for C mount 1/3” sensor cameras and miniature pinhole camera lenses. Additionally, Claresys customizes lenses for long-range surveillance in challenging environments, such as nuclear and high-temperature settings. Their optical technologies are versatile, suited for both close surveillance in buildings and vehicles as well as long-distance stake-outs. Claresys primarily serves clients in the defense, homeland security, and police sectors, distributing its products through a network that spans several countries, including the United Kingdom, the United States, Australia, and various nations in Europe. Established in 2007, the company is headquartered in Abingdon, United Kingdom.
NorthRow is a web-based platform designed to enhance risk management, compliance, and anti-fraud decisions for regulated businesses. It offers a suite of features that can be utilized independently or collectively, enabling users to conduct thorough checks on individuals, companies, and identity documents. The platform streamlines onboarding processes and enhances client due diligence by continuously monitoring customer profiles for changes, which helps businesses proactively manage regulatory risks. By accessing multiple data sources, NorthRow facilitates the verification of identities and authenticates critical documents such as passports and visas, ultimately improving customer experiences while ensuring compliance with regulatory requirements.
Eagle Genomics Ltd. specializes in providing data management and analysis solutions for the healthcare, pharmaceutical, biotech, and personal care sectors. Founded in 2008 and based in Cambridge, United Kingdom, with additional offices in the United States, Germany, and India, the company focuses on the management and analysis of genomic data, particularly through next-generation sequencing technologies. Its services encompass NGS data management, analysis, visualization, biomarker discovery, and custom software development. The company also offers pipeline design services and a web-based platform, ElasticAP, for managing life sciences research and development data in the cloud. With a unique blend of expertise in biology, bioinformatics, data science, and software engineering, Eagle Genomics helps clients in drug development, personal hygiene, and agri-tech industries maximize the value of their research and development data, addressing challenges associated with the increasing volume of life sciences data.
Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by the real-world impact of CRISPR technology. They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.
Perfectus Biomed is a microbiological services provider that specializes in customized and accredited microbiology testing. The company focuses on tailoring antimicrobial assays and developing bespoke methods for biofilm testing, recognizing that standard testing may not be suitable for all products. By adopting a research-based approach, Perfectus Biomed collaborates closely with clients to meet their specific testing needs while ensuring rapid turnaround times. Their customer-centric service includes regular feedback, consultancy, method development, and comprehensive report writing. Additionally, they produce conference abstracts and posters based on their research findings, reinforcing their commitment to delivering high-quality, personalized microbiological testing solutions.
SFH Oxford Ltd. is a UK-based company that specializes in developing and marketing innovative healthcare technologies aimed at improving the treatment of venous leg ulcers, a common chronic wound. Founded in 2011 and located in Didcot, the company offers a range of products, including Graducheck, a sensor-based technology that enhances the application of compression bandages, and AFT graduated compression socks, which ensure appropriate compression levels. Additionally, SFH Oxford produces K-gel, a wound dressing designed to aid in healing. The company is actively involved in clinical and field trials for several of its products, which are demonstrating promising results. SFH Oxford's leadership team possesses extensive experience in medical device technology and wound care, focusing on delivering optimized care solutions for both patients and healthcare professionals involved in venous leg ulcer management.
Tokamak Solutions UK Ltd. engages in providing technology for fusion neutron source to transmute nuclear waste. The company was founded in 2009 and is based in Abingdon, United Kingdom.
MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in medical technology. The company has developed CoagMax, a point-of-care monitor that enables home testing for prothrombin time (PT) and international normalized ratio (INR) blood tests. In addition, MicroVisk is engaged in the creation of Micro Electro Mechanical Sensors, targeting the international medical market. By focusing on innovative solutions for blood testing and medical device technologies, MicroVisk aims to enhance patient care and facilitate easier access to vital health information.
Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.
MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in medical technology. The company has developed CoagMax, a point-of-care monitor that enables home testing for prothrombin time (PT) and international normalized ratio (INR) blood tests. In addition, MicroVisk is engaged in the creation of Micro Electro Mechanical Sensors, targeting the international medical market. By focusing on innovative solutions for blood testing and medical device technologies, MicroVisk aims to enhance patient care and facilitate easier access to vital health information.
P2i Limited specializes in liquid repellent nano-coating technology, providing innovative solutions that enhance the performance of various products without altering their appearance or texture. Founded in 2003 and based in Abingdon, United Kingdom, P2i utilizes a unique pulsed plasma deposition process to create hydrophobic coatings that reduce the surface energy of materials, allowing liquids to bead up and roll off. This technology is applicable to a wide range of sectors, including electronics, textiles, lifestyle products, life sciences, filtration, energy, and military applications. P2i operates internationally, with facilities in the United States and Singapore, as well as application centers in China, serving customers looking to protect their products from water and other liquids.
MicroVisk Limited, founded in 2004 and based in Oxford, United Kingdom, specializes in medical technology. The company has developed CoagMax, a point-of-care monitor that enables home testing for prothrombin time (PT) and international normalized ratio (INR) blood tests. In addition, MicroVisk is engaged in the creation of Micro Electro Mechanical Sensors, targeting the international medical market. By focusing on innovative solutions for blood testing and medical device technologies, MicroVisk aims to enhance patient care and facilitate easier access to vital health information.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.
Microbial Solutions Limited offers a technology that can provide on-site treatment and disposal of MWFs which can unlock and release the replacement value of both the existing treatment technology and the associated logistics costs. The Microcycle™ technology is a powerful, patented biological degradation process that reduces waste MWFs to acceptable COD concentrations, removes toxicity and allows for the safe disposal of MWF as grey water to sewers on site. Through their offering, Microbial Solutions seeks to help their clients to cost-effectively meet their environmental responsibilities and to provide regulators with the tools to implement the regulations enshrining those responsibilities.
Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.
CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.
Orbital Optics specializes in the manufacture and sale of high-resolution optical cameras designed for space missions, catering to both the United Kingdom and international markets. The company focuses on producing compact and affordable space cameras that deliver high-quality images. In addition to its camera manufacturing, Orbital Optics offers consultancy services related to imaging systems and optical payloads, along with access to supporting ground station facilities.
Oxsensis Ltd. is a manufacturer of non-electrical optical sensors designed for extreme environments, focusing on applications in aerospace, power generation, oil and gas, and nuclear industries. Founded in 2003 and headquartered in Didcot, United Kingdom, the company specializes in optical pressure sensor systems, temperature transducers, and optical accelerometers. Its product lineup includes the Wave-Phire Dynamic Pressure Transducer for harsh atmospheres, the i-Phire 4 Channel Optical Interrogator Unit for converting optical signals into voltage signals, and S-Phire software for combustion monitoring. These sensors provide high sensitivity and immunity to electromagnetic interference, optimizing performance in demanding conditions. Oxsensis also supports various markets, including energy production, emissions monitoring, and high-temperature equipment health monitoring, with additional offices in the United States, Russia, China, and Japan.
CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutic products. Established in 2003, the company specializes in small-molecule inhibitors that target p300 and CBP proteins, as well as a deubiquitinase enzyme closely linked to prostate cancer. This enzyme modulates the androgen receptor pathway, which is critical in addressing resistance mechanisms encountered with existing prostate cancer treatments. CellCentric's therapies aim to treat various cancers, including castrate-resistant prostate cancer, lung cancer, bladder cancer, non-small cell lung cancer, breast cancer, and colon cancer. By targeting specific pathways and mechanisms, CellCentric seeks to provide effective treatment options for patients with challenging cancer types.
Novacta Biosystems Ltd, founded in 2003, specializes in the development of biopharmaceuticals aimed at treating bacterial infections, particularly those caused by drug-resistant strains. The company employs a dual business model that combines biocatalysis and microbial pathway engineering services with the discovery and development of novel small peptide molecules known as lantibiotics. These innovative therapies target various bacterial infections, including Clostridium difficile. By leveraging the expertise of GSK's Biotransformation and Natural Products scientific team, Novacta has established a robust infectious disease therapeutic pipeline, focusing on delivering effective anti-infective solutions.
Alopa is a pioneer and leader in the design, development, and deployment of infrastructure software solutions for end-to-end activation, management, and assurance of digital services over cable. Alopa Networks has been an industry driver in developing operations support software (OSS) solutions for broadband service providers that accelerate time-to-market for advanced network-based services and applications, including Internet telephone (VoIP), differentiated access, security, multimedia, and more. Alopa's combined family of products automates the complete life cycle of subscriber acquisition and service management by facilitating service creation, deployment, and assurance and security functions while, at the same time, accelerating revenue and lowering operating and capital expenses. Its flagship Alopa MetaServ(TM) platform is currently the only industry solution that automates the entire subscriber life cycle -- from equipment qualification through service creation and activation to customer support -- and integrates all layers of the IT infrastructure, including billing, order entry, customer care, and network management. It also provides secure provisioning for both PacketCable(TM) and CableHome(TM) networks, offering a framework for VoIP, multimedia services, and interactive gaming.